Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Interest Expenses (2016 - 2024)

Sunshine Biopharma filings provide 11 years of Interest Expenses readings, the most recent being $8529.0 for Q4 2024.

  • On a quarterly basis, Interest Expenses fell 71.67% to $8529.0 in Q4 2024 year-over-year; TTM through Sep 2025 was $8529.0, a 89.28% decrease, with the full-year FY2024 number at $8774.0, down 93.61% from a year prior.
  • Interest Expenses hit $8529.0 in Q4 2024 for Sunshine Biopharma, up from $245.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $195630.0 in Q2 2021 to a low of $2.0 in Q3 2022.
  • Median Interest Expenses over the past 5 years was $28328.0 (2022), compared with a mean of $39296.4.
  • Biggest five-year swings in Interest Expenses: plummeted 100.0% in 2022 and later soared 1926250.0% in 2023.
  • Sunshine Biopharma's Interest Expenses stood at $105436.0 in 2020, then crashed by 65.26% to $36630.0 in 2021, then fell by 27.53% to $26546.0 in 2022, then rose by 13.43% to $30110.0 in 2023, then crashed by 71.67% to $8529.0 in 2024.
  • The last three reported values for Interest Expenses were $8529.0 (Q4 2024), $245.0 (Q2 2024), and $49181.0 (Q1 2024) per Business Quant data.